Quick Takeaways
- This page summarizes William Garrett Nichols's Form 4 filing for Candel Therapeutics, Inc. (CADL).
- 3 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 02 Jul 2025, 16:30.
William Garrett Nichols - 30 Jun 2025 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)
- Signature
- /s/ Charles Schoch, as Attorney-In-Fact for William Garrett Nichols
- Issuer symbol
- CADL
- Transactions as of
- 30 Jun 2025
- Net transactions value
- -$2,929
- Form type
- 4
- Filing time
- 02 Jul 2025, 16:30:04 UTC
- Previous filing
- 20 Mar 2025
- Next filing
- 30 Jul 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"William Garrett Nichols filed Form 4 for Candel Therapeutics, Inc. (CADL) on 02 Jul 2025."
What Changed
- Previous filing in this sequence was filed on 20 Mar 2025.
- Current net transaction value: -$2,929.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer | C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM | /s/ Charles Schoch, as Attorney-In-Fact for William Garrett Nichols | 02 Jul 2025 | 0001618364 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CADL | Common Stock | Options Exercise | $1,007 | +781 | +1.5% | $1.29 | 53,274 | 30 Jun 2025 | Direct | F1 |
| transaction | CADL | Common Stock | Sale | $3,936 | -781 | -1.5% | $5.04 | 52,493 | 30 Jun 2025 | Direct | F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CADL | Stock Option (Right to Buy) | Options Exercise | $0 | -781 | -2.5% | $0.000000 | 30,314 | 30 Jun 2025 | Common Stock | 781 | $1.29 | Direct | F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024. |
| F2 | This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date. |